Results 131 to 140 of about 33,788 (287)

Effectiveness and tolerability of galcanezumab for migraine prevention in patients ≥65 years: A real‐life multicenter study

Headache: The Journal of Head and Face Pain, EarlyView.
Plain Language Summary This study shows that galcanezumab is equally effective and well‐tolerated in patients aged 65 and older as in younger patients, with a higher proportion of excellent responders in older patients. Despite having more baseline headache days, older patients responded well to the treatment, with age being linked to better outcomes ...
Julia Peris‐Subiza, Víctor Obach, Daniel Guisado‐Alonso, Fernando Velasco Juanes, Rocío Álvarez Escudero, María Martín Bujanda, Sonsoles Aranceta, Aintzine Ruisánchez, Natalia Roncero, Ane Mínguez‐Olaondo, Amaya Echeverria, Alba López‐Bravo, Ángel Luis Guerrero‐Peral, David García‐Azorín, Elisa Cuadrado‐Godia, Galca‐Only Study Group, Neus Fabregat, Marta Ruibal, Izaro Kortazar Zubizarreta, Nuria Riesco, Lucia González‐Fernández, Paula Manera, Agustín Oterino Duran, Yésica González‐Osorio, Santiago Fernández‐Fernández, Juan Carlos García‐Moncó, Isabel Fernández‐Pérez, Joan Jiménez‐Balado   +27 more
wiley   +1 more source

Reasons for patient reluctance to take preventive medications for migraine: Results of the OVERCOME (US) study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background This study was undertaken to evaluate patient reasons for nonadoption of migraine‐preventive medications. Despite clear recommendations and eligibility criteria for migraine‐preventive treatment by the American Headache Society and the availability of these treatments, many people with migraine are not taking appropriate ...
Jessica Ailani, Rose Okonkwo, Elizabeth Johnston, Helen Hochstetler, Betzaida Martinez, Anthony Zagar, Robert A. Nicholson, Bert B. Vargas, E. Jolanda Muenzel, Richard B. Lipton   +9 more
wiley   +1 more source

Retrospective analysis of the tolerability and effectiveness of rimegepant for the acute treatment of migraine in adolescents

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective This study aims to evaluate the tolerability and effectiveness of the off‐label use of rimegepant as acute migraine treatment in adolescents. Background Calcitonin gene‐related peptide (CGRP) levels are elevated during migraine attacks.
Konstantinos Tourlas, Sruthi Ilangovan, Chelsea White, Samantha L. Irwin, Sara Pavitt   +4 more
wiley   +1 more source

Efficacy and safety of rimegepant for the acute treatment of migraine in Black or African American adults: A post hoc pooled subgroup analysis from three randomized, placebo‐controlled clinical trials

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective This post hoc subgroup analysis was conducted using pooled data from three US‐based clinical trials to compare efficacy and safety of rimegepant 75 mg versus placebo in acute migraine in adults who are Black or African American.
Larry Charleston IV, Cynthia E. Armand, Teshamae S. Monteith, Hope L. O'Brien, Chandra C. Abbott, Glenn C. Pixton, Terence Fullerton   +6 more
wiley   +1 more source

A phase 1 study of the breast milk and plasma pharmacokinetics of zavegepant 10 mg intranasal dose in healthy lactating women

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective This study evaluated the pharmacokinetics of zavegepant in human breast milk and plasma following a single, 10 mg dose of zavegepant nasal spray. Background Zavegepant nasal spray is a member of the gepant class of medications; small molecule inhibitors of the calcitonin gene‐related peptide receptor.
Abhijeet Jakate, Yan Weng, Ani Shkrodova, Ogert Fisniku, Ding Ding, Kayce Morton, Benjamin Maligalig, Pamela Garnick, Jing Liu, Mohamed H. Shahin   +9 more
wiley   +1 more source

Integrating gepants into clinical practice for the acute treatment of migraine

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To assess the role of small‐molecule calcitonin gene–related peptide receptor antagonists (gepants) in the acute treatment of migraine, particularly in relation to triptan treatments. Background Triptans have established efficacy and are widely prescribed for the acute treatment of migraine.
Richard B. Lipton, David W. Dodick, Linda Davis, Stephanie J. Nahas, Peter J. Goadsby   +4 more
wiley   +1 more source

Calcitonin gene-related peptide receptor (CGRP receptor) [PDF]

Science-Business eXchange, 2011
openaire   +1 more source

Novel optimization of multi‐mechanistic approaches for the acute treatment of a migraine attack: A review

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To highlight key factors required to optimize multi‐mechanistic approaches with oral combination treatments for the acute management of a migraine attack. Background Given the complex multi‐factorial nature of migraine, combining treatments with different mechanisms of action should improve outcomes compared to monotherapies, but ...
Stephen Silberstein, Alan M. Rapoport
wiley   +1 more source

Microneedles for the treatment of migraine and orofacial pain: A narrative review

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Background Migraine is a common neurological disorder and a primary headache condition. Despite its central origin, migraine pain may be referred to the orofacial region via trigeminal pathways, resulting in phenotypic overlap with other orofacial pain (OFP) conditions.
Baicheng Cao, Qiuyi Chen, Yuhan Liu, Ruozhou Wu, Bin Li, Qing Cai, Lu Liu   +6 more
wiley   +1 more source

Ion channels in migraine disorders [PDF]

, 2018
Pietrobon, Daniela
core   +1 more source